Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIPISAFE: Nivolumab and Ipilimumab in dMMR/MSI Metastatic Colorectal Cancer
NCT04730544Phase 2Active, not recruiting
- Sponsor
- GERCOR
- Start
- May 2021
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in colorectal cancer (CRC), sponsored by GERCOR. Started May 2021; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04730544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04730544.